

[\[Latest Headlines | Market Overview | News Alerts \]](#)

Wednesday February 20, 9:12 am Eastern Time

Press Release*SOURCE: ProteoTech, Inc.***ProteoTech Receives \$2.78 Million in NIH Research Funding to Study the Cause, Prevention and Treatment of Brain Amyloid Protein Deposits Associated With Alzheimer's Disease**

KIRKLAND, Wash., Feb 20 /PRNewswire/ -- The National Institutes of Health (NIH) has funded two research programs at ProteoTech Inc. for a total of \$2.78 million that will lead to (1) innovative therapeutics for the prevention and treatment of brain amyloid protein deposits present in all patients with Alzheimer's disease, and (2) a closer understanding of the mechanisms involved in Alzheimer's amyloid brain plaque formation and persistence. Amyloid plaques are one of the major pathological lesions found in the brains of all patients with Alzheimer's disease, and accumulation of amyloid protein deposits in brain is believed to lead to memory loss and dysfunction.

From the National Institute of Aging, ProteoTech ("Proteoglycan Technologies") Inc. has received a \$1.69 million Phase II Small Business Innovative Research (SBIR) award to further develop a plant-derived therapeutic for the treatment of Alzheimer's disease and related disorders. PTI-777 is derived from a plant that has potent amyloid inhibitory activity both in vitro and in animal models. ProteoTech has previously demonstrated that such plant-derived components cause a rapid remarkable disruption and clearance of pre-formed brain amyloid plaques in a transgenic mouse model of Alzheimer's disease. The lead therapeutic derived from this plant material, known as Exebryl(TM), is currently being development by ProteoTech scientists as a drug for the treatment of Alzheimer's disease, and is believed to offer new strategies for treating Alzheimer's patients in early, as well as mid-to-late stage disease. The project "PTI-777: A Potent Amyloid Inhibiting Agent for the Treatment of Alzheimer's Disease and Other Amyloidoses" is headed by Gerardo Castillo, Ph.D., Director of Biochemistry at ProteoTech.

Additionally, ProteoTech has been awarded a \$1.09 million Phase II SBIR award from the National Institute of Aging to further identify the mechanisms involved in brain amyloid plaque formation, as well as develop rapid in vitro screening and non-transgenic animal models for identifying new anti-amyloid plaque therapeutics. ProteoTech scientists have successfully formed the world's first artificial Alzheimer's plaques in a "test-tube" and have determined the process and components involved to form amyloid plaques within a short period. The project "A Rodent Model of Alzheimer's Amyloid Plaque Persistence In Vivo" is headed by Alan Snow, Ph.D., President & CSO at ProteoTech.

Confirmation of ProteoTech's cutting-edge research discovery and development capabilities is the fact that during the last 3 years ProteoTech has been awarded 7 SBIR grant awards from the NIH. ProteoTech is a private drug discovery and research development Company focused on therapeutics and diagnostics for specific human diseases, which involve "proteoglycans" in the disease pathogenesis. Proteoglycans are synthesized by virtually all cells of the body and play significant roles in the pathogenesis of a number of human diseases. ProteoTech is in pre-clinical development of therapeutics for Alzheimer's disease, Parkinson's disease, prion diseases, type 2 diabetes, and systemic amyloidosis.

Note: This news release contains forward-looking statements that involve risks and uncertainties, including without limitation to, risks associated with clinical development and regulatory approvals, the continued ability of the Company to raise funds needed for research, development and patent protection, and the Company's ability to establish and maintain collaborative agreements with third parties. The information contained in this press release should be evaluated in conjunction with the Company's other disclosure documents.

SOURCE: ProteoTech, Inc.[Email this story](#) - [Most-emailed articles](#) - [Most-viewed articles](#)**Related News Categories:** [biotech](#), [medical/pharmaceutical](#) [Help](#)Copyright © 2002 Yahoo! Inc. All rights reserved. [Privacy Policy](#) - [Terms of Service](#)Copyright © 2002 PR Newswire. All rights reserved. Reproduction or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
[Questions or Comments?](#)